Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov
MDT The article is a Form 8-K filing detailing corporate events such as officer appointments, compensation changes, and the completion of a separation of a subsidiary. It also includes voting results from an annual general meeting. The information is factual and does not express a directional opinion on the stock's future performance. MMED The article mentions the completion of MiniMed Group, Inc.'s separation from Medtronic plc. This is a factual announcement regarding corporate restructuring and does not provide an opinion on the stock's performance.

8-K — Medtronic plc

Accession: 0001628280-26-066291

Filed: 2026-10-19

Period: 2026-10-15

CIK: 0001613103

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Submission of Matters to a Vote of Security Holders

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — mdt-20261015.htm (Primary)

EX-99.1 (exhibit991-statementdatedo.htm)

GRAPHIC — IMAGE 0 (image_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: mdt-20261015.htm · Sequence: 1

mdt-20261015

0001613103Medtronic plcH91 VY19false00016131032026-10-152026-10-150001613103us-gaap:CommonStockMember2026-10-152026-10-150001613103mdt:A1.125SeniorNotesDue2027Member2026-10-152026-10-150001613103mdt:A0.375SeniorNotesDue2028Member2026-10-152026-10-150001613103mdt:A3.000SeniorNotesDue2028Member2026-10-152026-10-150001613103mdt:A3.650SeniorNotesDue2029Member2026-10-152026-10-150001613103mdt:A2.950SeniorNotesDue2030Member2026-10-152026-10-150001613103mdt:A1.625SeniorNotesDue2031Member2026-10-152026-10-150001613103mdt:A1.000SeniorNotesDue2031Member2026-10-152026-10-150001613103mdt:A3.125SeniorNotesDue2031Member2026-10-152026-10-150001613103mdt:A0.750SeniorNotesDue2032Member2026-10-152026-10-150001613103mdt:A3.375SeniorNotesDue2034Member2026-10-152026-10-150001613103mdt:A3.875SeniorNotesDue2036Member2026-10-152026-10-150001613103mdt:A2.250SeniorNotesDue2039Member2026-10-152026-10-150001613103mdt:A1.500SeniorNotesDue2039Member2026-10-152026-10-150001613103mdt:A1.375SeniorNotesDue2040Member2026-10-152026-10-150001613103mdt:A4.150SeniorNotesDue2043Member2026-10-152026-10-150001613103mdt:A4.200SeniorNotesDue2045Member2026-10-152026-10-150001613103mdt:A1.750SeniorNotesDue2049Member2026-10-152026-10-150001613103mdt:A1.625SeniorNotesDue2050Member2026-10-152026-10-150001613103mdt:A4.150SeniorNotesDue2053Member2026-10-152026-10-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

FORM 8-K

_____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2026

_____________________________

Medtronic plc

(Exact name of Registrant as Specified in its Charter)

_____________________________

Ireland 1-36820 98-1183488

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Building Two

Parkmore Business Park West

Galway, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol Name of each exchange on which registered

Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange

1.125% Senior Notes due 2027 MDT/27 New York Stock Exchange

0.375% Senior Notes due 2028 MDT/28 New York Stock Exchange

3.000% Senior Notes due 2028 MDT/28A New York Stock Exchange

3.650% Senior Notes due 2029 MDT/29 New York Stock Exchange

2.950% Senior Notes due 2030 MDT/30 New York Stock Exchange

1.625% Senior Notes due 2031 MDT/31 New York Stock Exchange

1.000% Senior Notes due 2031 MDT/31A New York Stock Exchange

3.125% Senior Notes due 2031 MDT/31B New York Stock Exchange

0.750% Senior Notes due 2032 MDT/32 New York Stock Exchange

3.375% Senior Notes due 2034 MDT/34 New York Stock Exchange

3.875% Senior Notes due 2036 MDT/36 New York Stock Exchange

2.250% Senior Notes due 2039 MDT/39A New York Stock Exchange

1.500% Senior Notes due 2039 MDT/39B New York Stock Exchange

1.375% Senior Notes due 2040 MDT/40A New York Stock Exchange

4.150% Senior Notes due 2043 MDT/43A New York Stock Exchange

4.200% Senior Notes due 2045 MDT/45 New York Stock Exchange

1.750% Senior Notes due 2049 MDT/49 New York Stock Exchange

1.625% Senior Notes due 2050 MDT/50 New York Stock Exchange

4.150% Senior Notes due 2053 MDT/53 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 15, 2026, the Board of Directors (the "Board") of Medtronic plc (the “Company”) approved the appointment of Michael Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas, and Global Commercial Operations to the role of President, Medtronic, effective October 14, 2026. In this expanded role, Mr. Marinaro will continue with his current responsibilities, in addition to exercising oversight responsibility for the Company’s Greater China operations, which will continue to be managed locally by Alex Gu, Senior Vice President and President, Greater China. Mr. Marinaro will continue to report to Geoffrey S. Martha, who will continue to serve as the Company’s Chairman of the Board of Directors and Chief Executive Officer.

In connection with Mr. Marinaro’s appointment as President, Medtronic, the Compensation and Talent Committee (the "Committee") of the Board approved changes to his compensation, including an increase in Mr. Marinaro's annual base salary to $1,000,000 for all of fiscal year 2027. Mr. Marinaro's target annual incentive opportunity under the Medtronic Incentive Plan will continue to equal 100% of his annual base salary. In addition, the Committee approved supplemental fiscal year 2027 long-term incentive awards with an aggregate target value of approximately $3.25 million, consisting of (i) a performance share unit award with a target value of $1.625 million, (ii) a stock option award with a grant date value of $975,000 and (iii) a restricted stock unit award with a value of $650,000, each to be granted on November 2, 2026 pursuant to the Company’s 2021 Medtronic plc Long-Term Incentive Plan (the "Plan"). The performance share unit award will vest on April 27, 2029 based on the Company’s fiscal year 2027 through fiscal year 2029 performance. The stock option award will vest in four equal annual installments beginning August 3, 2027, and will have a ten-year term. The restricted stock unit award will vest in full on August 3, 2029. The awards are subject to the terms and conditions of the applicable award agreements and the Plan.

Item 5.07. Submission of Matters to a Vote of Security Holders

On October 15, 2026, the Company held its Annual General Meeting in order to: (1) elect, by separate resolutions, twelve directors, each to hold office until the 2027 Annual General Meeting of the Company and until his or her successor is elected; (2) ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2027 and authorize, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration; (3) approve, in a non-binding advisory vote, the compensation of the Company's named executive officers; (4) renew the Board’s authority to issue shares; (5) renew the Board’s authority to opt out of pre-emption rights; and (6) authorize the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares.

At the close of business on August 21, 2026, the record date for the Annual General Meeting, 1,279,980,861 Company ordinary shares, par value $0.0001 per share (“ordinary shares”), were outstanding and entitled to vote. The holders of a total of 1,116,484,432 ordinary shares were present at the Annual General Meeting, either in person or by proxy, constituting a quorum.

The final voting results and the votes used to determine the results for each proposal are set forth below:

1.The shareholders elected, by separate resolutions, each of the twelve nominees to the Board of Directors to hold office until the 2027 Annual General Meeting of the Company and until his or her successor is elected, as follows:

FOR AGAINST ABSTAIN BROKER

NON-VOTE

Craig Arnold 836,722,939 162,390,057 2,507,270 114,864,166

Scott C. Donnelly 936,917,038 64,069,780 633,448 114,864,166

Lidia L. Fonseca 951,681,008 48,656,066 1,283,192 114,864,166

John P. Groetelaars 945,082,041 55,865,998 672,227 114,864,166

Randall J. Hogan, III 957,360,867 43,601,371 658,028 114,864,166

William R. Jellison 992,612,800 8,359,017 648,449 114,864,166

Joon S. Lee, M.D. 990,968,796 10,046,047 605,423 114,864,166

Gregory P. Lewis 983,300,542 17,675,905 643,819 114,864,166

Kevin E. Lofton 990,233,684 10,780,071 606,511 114,864,166

Geoffrey S. Martha 932,823,586 65,265,168 3,531,512 114,864,166

Elizabeth G. Nabel, M.D. 948,053,173 53,008,869 558,224 114,864,166

Kendall J. Powell 883,777,900 116,166,175 1,676,191 114,864,166

2. The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as Medtronic’s independent auditor for fiscal year 2027 and authorized, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration.

FOR AGAINST ABSTAIN

1,008,390,318 107,394,197 699,917

3. The shareholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers.

FOR AGAINST ABSTAIN BROKER NON-VOTE

936,336,164 62,496,763 2,787,339 114,864,166

4. The shareholders approved renewal of the Board’s authority to issue shares under Irish law.

FOR AGAINST ABSTAIN

1,100,821,210 14,299,857 1,363,365

5. The shareholders approved renewal of the Board’s authority to opt out of pre-emption rights under Irish law.

FOR AGAINST ABSTAIN

1,036,661,831 75,816,920 4,005,681

6. The shareholders authorized the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares.

FOR AGAINST ABSTAIN

1,081,959,682 31,665,910 2,858,840

Item 7.01. Regulation FD Disclosure

On October 15, 2026, the Company announced that the exchange offer relating to the separation of MiniMed Group, Inc. had settled and that the separation was complete. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits.

(d) List of Exhibits

Exhibit Number Description

99.1

Press Release dated October 15, 2026.

104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

Date: October 19, 2026 By /s/ Michelle Quinn

Michelle Quinn

Executive Vice President, General Counsel and Corporate Secretary

EX-99.1

EX-99.1

Filename: exhibit991-statementdatedo.htm · Sequence: 2

Document

Exhibit 99.1

Medtronic Completes Separation of MiniMed Group, Inc.

GALWAY, Ireland, October 15, 2026 – Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).

“I’m incredibly proud of what MiniMed and Medtronic have accomplished together and the meaningful difference we’ve made in the lives of people with diabetes,” said Geoff Martha, Medtronic Chairman and Chief Executive Officer. “Today’s separation marks an important milestone for both companies as each moves forward with a clear strategic focus. For Medtronic, that means putting the full weight of our organization behind advancing innovation and fueling growth across our Cardiovascular, Neuroscience and Surgical portfolios.”

As separately announced yesterday, Medtronic has elected to exchange all of its remaining interest in MiniMed (totaling 252,813,348 shares of MiniMed common stock) in its previously announced offer to exchange shares of MiniMed common stock for outstanding Medtronic ordinary shares, which was 5.4x subscribed. The separation of MiniMed from Medtronic is now complete.

Full details of the results of the exchange offer are available in a separate press release issued yesterday. The exchange agent will promptly credit newly issued shares of MiniMed common stock in book-entry form to accounts maintained by the MiniMed transfer agent for tendering shareholders whose Medtronic ordinary shares were accepted in the exchange offer. Checks in lieu of fractional shares of MiniMed common stock will be delivered after the exchange agent has aggregated all fractional shares and sold them in the open market.

Goldman Sachs & Co. LLC and BofA Securities, Inc. served as dealer managers for the exchange offer.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated benefits of the exchange offer, Medtronic’s ability to successfully realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders for U.S. federal income tax purposes), MiniMed’s ability to succeed as an independent publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in Medtronic’s and MiniMed’s periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

Contacts:

Justin Paquette

Public Relations

+1-612-271-7935

Ingrid Goldberg

Investor Relations

+1-763-505-2696

GRAPHIC — IMAGE 0

GRAPHIC

Filename: image_0.jpg · Sequence: 7

Binary file (150135 bytes)

Download image_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Document And Entity Information

Oct. 15, 2026

Entity Information [Line Items]

Document Type

8-K

Document Period End Date

Oct. 15, 2026

Entity Incorporation, State or Country Code

L2

Entity File Number

1-36820

Entity Tax Identification Number

98-1183488

Entity Address, Address Line One

Building Two

Entity Address, City or Town

Galway

Entity Address, Country

IE

Country Region

353

City Area Code

1

Local Phone Number

438-1700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0001613103

Entity Registrant Name

Medtronic plc

Entity Address, Postal Zip Code

H91 VY19

Amendment Flag

false

Entity Address, Address Line Two

Parkmore Business Park West

Ordinary shares, par value $0.0001 per share

Entity Information [Line Items]

Title of 12(b) Security

Ordinary shares, par value $0.0001 per share

Trading Symbol

MDT

Security Exchange Name

NYSE

1.125% Senior Notes due 2027

Entity Information [Line Items]

Title of 12(b) Security

1.125% Senior Notes due 2027

Trading Symbol

MDT/27

Security Exchange Name

NYSE

0.375% Senior Notes due 2028

Entity Information [Line Items]

Title of 12(b) Security

0.375% Senior Notes due 2028

Trading Symbol

MDT/28

Security Exchange Name

NYSE

3.000% Senior Notes due 2028

Entity Information [Line Items]

Title of 12(b) Security

3.000% Senior Notes due 2028

Trading Symbol

MDT/28A

Security Exchange Name

NYSE

1.625% Senior Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

1.625% Senior Notes due 2031

Trading Symbol

MDT/31

Security Exchange Name

NYSE

1.000% Senior Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

1.000% Senior Notes due 2031

Trading Symbol

MDT/31A

Security Exchange Name

NYSE

0.750% Senior Notes due 2032

Entity Information [Line Items]

Title of 12(b) Security

0.750% Senior Notes due 2032

Trading Symbol

MDT/32

Security Exchange Name

NYSE

2.250% Senior Notes due 2039

Entity Information [Line Items]

Title of 12(b) Security

2.250% Senior Notes due 2039

Trading Symbol

MDT/39A

Security Exchange Name

NYSE

1.500% Senior Notes due 2039

Entity Information [Line Items]

Title of 12(b) Security

1.500% Senior Notes due 2039

Trading Symbol

MDT/39B

Security Exchange Name

NYSE

1.375% Senior Notes due 2040

Entity Information [Line Items]

Title of 12(b) Security

1.375% Senior Notes due 2040

Trading Symbol

MDT/40A

Security Exchange Name

NYSE

1.750% Senior Notes due 2049

Entity Information [Line Items]

Title of 12(b) Security

1.750% Senior Notes due 2049

Trading Symbol

MDT/49

Security Exchange Name

NYSE

1.625% Senior Notes due 2050

Entity Information [Line Items]

Title of 12(b) Security

1.625% Senior Notes due 2050

Trading Symbol

MDT/50

Security Exchange Name

NYSE

3.375% Senior Notes due 2034

Entity Information [Line Items]

Title of 12(b) Security

3.375% Senior Notes due 2034

Trading Symbol

MDT/34

Security Exchange Name

NYSE

3.125% Senior Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

3.125% Senior Notes due 2031

Trading Symbol

MDT/31B

Security Exchange Name

NYSE

3.650% Senior Notes due 2029

Entity Information [Line Items]

Title of 12(b) Security

3.650% Senior Notes due 2029

Trading Symbol

MDT/29

Security Exchange Name

NYSE

2.950% Senior Notes due 2030

Entity Information [Line Items]

Title of 12(b) Security

2.950% Senior Notes due 2030

Trading Symbol

MDT/30

Security Exchange Name

NYSE

4.150% Senior Notes due 2043

Entity Information [Line Items]

Title of 12(b) Security

4.150% Senior Notes due 2043

Trading Symbol

MDT/43A

Security Exchange Name

NYSE

4.200% Senior Notes due 2045

Entity Information [Line Items]

Title of 12(b) Security

4.200% Senior Notes due 2045

Trading Symbol

MDT/45

Security Exchange Name

NYSE

4.150% Senior Notes due 2053

Entity Information [Line Items]

Title of 12(b) Security

4.150% Senior Notes due 2053

Trading Symbol

MDT/53

Security Exchange Name

NYSE

3.875% Senior Notes due 2036

Entity Information [Line Items]

Title of 12(b) Security

3.875% Senior Notes due 2036

Trading Symbol

MDT/36

Security Exchange Name

NYSE

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Region code of country

+ References

No definition available.

+ Details

Name:

dei_CountryRegion

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.125SeniorNotesDue2027Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A0.375SeniorNotesDue2028Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A3.000SeniorNotesDue2028Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.625SeniorNotesDue2031Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.000SeniorNotesDue2031Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A0.750SeniorNotesDue2032Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A2.250SeniorNotesDue2039Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.500SeniorNotesDue2039Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.375SeniorNotesDue2040Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.750SeniorNotesDue2049Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A1.625SeniorNotesDue2050Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A3.375SeniorNotesDue2034Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A3.125SeniorNotesDue2031Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A3.650SeniorNotesDue2029Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A2.950SeniorNotesDue2030Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A4.150SeniorNotesDue2043Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A4.200SeniorNotesDue2045Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A4.150SeniorNotesDue2053Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=mdt_A3.875SeniorNotesDue2036Member

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type: